ATE478678T1 - Behandlung von amyotrohper lateralsklerose - Google Patents

Behandlung von amyotrohper lateralsklerose

Info

Publication number
ATE478678T1
ATE478678T1 AT05747975T AT05747975T ATE478678T1 AT E478678 T1 ATE478678 T1 AT E478678T1 AT 05747975 T AT05747975 T AT 05747975T AT 05747975 T AT05747975 T AT 05747975T AT E478678 T1 ATE478678 T1 AT E478678T1
Authority
AT
Austria
Prior art keywords
treatment
lateral sclerosis
amyotrohper
relates
als
Prior art date
Application number
AT05747975T
Other languages
English (en)
Inventor
Peter Carmeliet
Original Assignee
Vib Vzw
Life Sciences Res Partners Vzw
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vib Vzw, Life Sciences Res Partners Vzw filed Critical Vib Vzw
Application granted granted Critical
Publication of ATE478678T1 publication Critical patent/ATE478678T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1858Platelet-derived growth factor [PDGF]
    • A61K38/1866Vascular endothelial growth factor [VEGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0085Brain, e.g. brain implants; Spinal cord
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Automatic Cycles, And Cycles In General (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AT05747975T 2004-05-27 2005-05-27 Behandlung von amyotrohper lateralsklerose ATE478678T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04102334 2004-05-27
PCT/EP2005/052430 WO2005117946A1 (en) 2004-05-27 2005-05-27 Treatment of amyotrophic lateral sclerosis

Publications (1)

Publication Number Publication Date
ATE478678T1 true ATE478678T1 (de) 2010-09-15

Family

ID=34968798

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05747975T ATE478678T1 (de) 2004-05-27 2005-05-27 Behandlung von amyotrohper lateralsklerose

Country Status (17)

Country Link
US (2) US7687463B2 (de)
EP (1) EP1755647B1 (de)
JP (2) JP5537770B2 (de)
AT (1) ATE478678T1 (de)
AU (1) AU2005249234B2 (de)
CA (1) CA2568158A1 (de)
CY (1) CY1111654T1 (de)
DE (1) DE602005023155D1 (de)
DK (1) DK1755647T3 (de)
ES (1) ES2351804T3 (de)
HR (1) HRP20100555T1 (de)
ME (1) ME01870B (de)
PL (1) PL1755647T3 (de)
PT (1) PT1755647E (de)
RS (1) RS51481B (de)
SI (1) SI1755647T1 (de)
WO (1) WO2005117946A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1272208B1 (de) * 2000-04-12 2011-10-05 VIB vzw Verwendung von vegf 165 und homologen zur behandlung von neurologischen störungen
EP1755647B1 (de) 2004-05-27 2010-08-25 VIB, vzw Behandlung von amyotrohper lateralsklerose
WO2012048330A2 (en) * 2010-10-08 2012-04-12 The Mclean Hospital Corporation Treatment of motor neuron disease
CA3132310C (en) * 2012-08-07 2024-01-09 Children's Medical Center Corporation Potassium channel openers for treating neurodegenerative diseases
US20140155816A1 (en) * 2012-10-09 2014-06-05 Eu Sol Biotech Co., Ltd. Method for treating brain injury or stroke
CN119587584A (zh) * 2013-10-01 2025-03-11 卡迪马干细胞有限公司 从人多能干细胞定向分化星形胶质细胞用于肌萎缩侧索硬化(als)的治疗和药物筛选
KR102879823B1 (ko) * 2022-03-24 2025-11-03 주식회사 아이엔테라퓨틱스 인비보 패치 클램프 기법을 이용한 전기생리학적 약효 평가법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5332671A (en) * 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
EP0969875B1 (de) 1997-01-17 2008-11-26 Aventis Pharma S.A. Gen-einführung in mark-motoneuronen mittels eines nackten dnas
CA2322748A1 (en) 1998-03-13 1999-09-16 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
ATE405651T1 (de) 1998-03-17 2008-09-15 Genentech Inc Zu vegf und bmp1 homologe polypeptide
JP2002526083A (ja) 1998-09-23 2002-08-20 オックスフォード バイオメディカ(ユーケイ)リミテッド ポリヌクレオチド構築物およびその使用
CA2365434A1 (en) 1999-04-15 2000-10-26 St. Elizabeth's Medical Center Of Boston Angiogenic growth factors for treatment of peripheral neuropathy
US7125856B1 (en) * 1999-04-15 2006-10-24 St. Elizabeth's Medical Center Of Boston, Inc. Angiogenic growth factors for treatment of peripheral neuropathy
EP1272208B1 (de) * 2000-04-12 2011-10-05 VIB vzw Verwendung von vegf 165 und homologen zur behandlung von neurologischen störungen
US7981863B2 (en) * 2001-09-19 2011-07-19 Neuronova Ab Treatment of Parkinson's disease with PDGF
AU2003271883A1 (en) * 2002-10-04 2004-04-23 Oxford Biomedica (Uk) Limited Vector system
EP1755647B1 (de) * 2004-05-27 2010-08-25 VIB, vzw Behandlung von amyotrohper lateralsklerose

Also Published As

Publication number Publication date
JP5537770B2 (ja) 2014-07-02
EP1755647A1 (de) 2007-02-28
SI1755647T1 (sl) 2011-01-31
DE602005023155D1 (de) 2010-10-07
AU2005249234B2 (en) 2010-08-05
ES2351804T3 (es) 2011-02-10
JP2012111774A (ja) 2012-06-14
US20080279906A1 (en) 2008-11-13
US20100152116A1 (en) 2010-06-17
ME01870B (me) 2011-04-30
AU2005249234A1 (en) 2005-12-15
HRP20100555T1 (hr) 2011-01-31
DK1755647T3 (da) 2010-10-11
WO2005117946A1 (en) 2005-12-15
RS51481B (sr) 2011-04-30
CA2568158A1 (en) 2005-12-15
CY1111654T1 (el) 2015-10-07
US7863246B2 (en) 2011-01-04
EP1755647B1 (de) 2010-08-25
US7687463B2 (en) 2010-03-30
PT1755647E (pt) 2010-09-29
PL1755647T3 (pl) 2011-01-31
JP2008500312A (ja) 2008-01-10

Similar Documents

Publication Publication Date Title
CY1111654T1 (el) Θεραπευτικη αγωγη πλαγιας μυατροφικης σκληρυνσης
ATE489957T1 (de) Mittel zur behandlung von entzündlichen erkrankungen
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
DE602006021535D1 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer-krankheit
DOP2015000043A (es) Agentes inductores de apoptosis para el tratamiento de cáncer y enfermedades inmunes y autoinmunes
ATE457989T1 (de) Bi- und trizyklische substituierte phenyl- methanone als inhibitoren von glycin-i (glyt-1)- transportern zur behandlung der alzheimer- krankheit
MX2019012154A (es) Agentes inductores de apotosis para el tratamiento de cancer y enfermedades inmunes y autoinmunes.
ATE519488T1 (de) Aminopyrazin-analoga zur behandlung von glaukomen und anderen durch rho-kinase verursachten krankheiten
DE60325209D1 (de) Diarylharnstoffderivate, die sich zur behandlung von proteinkinaseabhängigen krankheiten eignen
EP1622633A4 (de) Behandlung von t-zell-vermittelten krankheiten
EA200700382A1 (ru) Фунгицидные композиции
DE602004026891D1 (de) Tlr7-liganden zur behandlung von hepatitis c
ATE418271T1 (de) Verfahren zur verringerung des exkrementgeruchs von heimtieren
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
ATE544449T1 (de) Neue verwendung von peptidverbindungen zur behandlung von amyothropher lateralsklerose
ATE319439T1 (de) Mittel zur behandlung von erkrankungen des tracheo-bronchialtraktes, insbesondere der copd
EA200600374A1 (ru) Замещённые пиперидинофенилоксазолидиноны, обладающие противомикробной активностью, с повышенной in vivo эффективностью
ATE482706T1 (de) Behandlung bakterieller erkrankungen der atmungsorgane durch lokale applikation von fluorchinolonen
ATE398398T1 (de) Nahrungsmittelzusatz
ATE526970T1 (de) Behandlung von mastitis
FR2867026B1 (fr) Composition phytosanitaire destinee au traitement antifongique des cultures.
ATE343387T1 (de) S-methyl-dihydro-ziprasidon zur behandlung von augenerkrankungen.
DE502004012196D1 (de) Verwendung von isorhamnetin zur behandlung von depressiven verstimmungen und erkrankungen
ATE478707T1 (de) Kim-1-antikörper zur behandlung von th2- vermittelten erkrankungen
DE602004028497D1 (de) Verwendung von ciclesonid zur behandlung von entzündlichen darmerkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1755647

Country of ref document: EP